Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）

Inclusion Criteria: * Males or females, ≥ 18 years of age at the time of signing the informed consent document； * Patients with moderate-to-severe plaque psoriasis：Simultaneously meet (1)and (2): (1)PASI≥ 3；(2) DLQI ≥ 6； * Subject is a candidate for phototherapy and/or systemic therapy * Patients who wish to be treated with Apremilast and sign the informed consent Exclusion Criteria: * Allergy to Apremilast or any component of the study drug； * Use of phototherapy within 4 weeks prior to randomization；Use of systemic drugs or biologic agents within 4 half-life periods prior to randomization；Patients with inadequate response or intolerance to previous systemic therapy do not need to consider drug washout； * Currently using potent cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin, etc.)； * History of substance abuse, suicide attempts, or mental illness； * Patients who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period； * Pustular type, erythroderma type and other psoriasis patients； * Other circumstances that investigators don't consider appropriate to include.